Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 6/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.51 |
| ▸ | MME | P08473 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | CPA1 | P15085 | 1/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | IL2 | P60568 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1081372 | 1.00 | FOLH1 (0.54) | FOLH1NAALAD2ACESLC7A5MME | |
| SCHEMBL31533362 | 1.00 | FOLH1 (0.54) | FOLH1NAALAD2ACESLC7A5MME | |
| SCHEMBL31533361 | 1.00 | FOLH1 (0.54) | FOLH1NAALAD2ACESLC7A5MME | |
| SCHEMBL246177 | 0.87 | FOLH1 (0.51) | FOLH1NAALAD2ACESLC7A5MME | |
| SCHEMBL20726 | 0.87 | FOLH1 (0.51) | FOLH1NAALAD2ACESLC7A5MME | |
| SCHEMBL23704504 | 0.87 | FOLH1 (0.51) | FOLH1NAALAD2ACESLC7A5MME | |
| SCHEMBL29746410 | 0.87 | FOLH1 (0.51) | FOLH1NAALAD2ACESLC7A5MME | |
| SCHEMBL626035 | 0.86 | MME (0.54) | FOLH1NAALAD2ACEMMEMEN1 | |
| SCHEMBL4880143 | 0.86 | MME (0.54) | FOLH1NAALAD2ACEMMEMEN1 | |
| SCHEMBL5560323 | 0.86 | MME (0.54) | FOLH1NAALAD2ACEMMEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | claimed |
| US-20240033366-A1 | FUNCTIONALIZED SHIGA TOXIN B-SUBUNIT (STxB) PROTEINS AND CONJUGATES THEREOF | INSTITUT CURIE (FR) | 2024-02-01 | — | — | US | disclosed |
| US-20220226269-A1 | METHODS AND COMPOSITIONS FOR MODULATION OF AN INTERSPECIES GUT BACTERIAL PATHWAY FOR LEVODOPA METABOLISM | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-07-21 | — | — | US | disclosed |
| CN-112752740-A | Process for the preparation of fluoromethyl-18 labelled radiopharmaceutical agents using selective azide substitution and precursor scavenging | BIK治疗公司 | 2021-05-04 | — | — | CN | disclosed |
| WO-2020252257-A1 | METHODS AND COMPOSITIONS FOR MODULATION OF AN INTERSPECIES GUT BACTERIAL PATHWAY FOR LEVODOPA METABOLISM | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020059986-A1 | METHOD FOR PREPARING FLUORINE-18-LABELED FLUOROMETHYL-SUBSTITUTED RADIOPHARMACEUTICALS USING SELECTIVE AZIDE SUBSTITUTION REACTION AND PRECURSOR SCAVENGING | 주식회사 바이오이미징코리아 | 2020-03-26 | — | — | WO | disclosed |
| US-20140309424-A1 | DIRECT SYNTHESIS OF 18F-FLUOROMETHOXY COMPOUNDS FOR PET IMAGING AND THE PROVISION OF NEW PRECURSORS FOR DIRECT RADIOSYNTHESIS OF PROTECTED DERIVATIVES OF O-([18F] FLUOROMETHYL) TYROSINE | PIRAMAL IMAGING SA (CH) | 2014-10-16 | — | — | US | disclosed |
| EP-2751087-A1 | DIRECT SYNTHESIS OF 18F-FLUOROMETHOXY COMPOUNDS FOR PET IMAGING AND THE PROVISION OF NEW PRECURSORS FOR DIRECT RADIOSYNTHESIS OF PROTECTED DERIVATIVES OF O-([18F]FLUOROMETHYL)TYROSINE | Piramal Imaging SA (CH) | 2014-07-09 | — | — | EP | disclosed |
| EP-2661321-A1 | MODULAR SYSTEM FOR RADIOSYNTHESIS WITH MULTI-RUN CAPABILITIES AND REDUCED RISK OF RADIATION EXPOSURE | Siemens Medical Solutions USA, Inc. (US) | 2013-11-13 | — | — | EP | disclosed |
| US-20130149243-A1 | METHOD FOR PRODUCTION OF F-18 LABELED GLUTAMIC ACID DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
| EP-0414730-A4 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | — | 1993-06-16 | — | — | EP | disclosed |
| EP-0451422-A1 | Pharmaceutically active fluoromethyltyrosine compounds | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-10-16 | — | — | EP | disclosed |
| EP-0451422-A1 | Pharmaceutically active fluoromethyltyrosine compounds | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-10-16 | — | — | EP | disclosed |
| EP-0414730-A1 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | Mills, Randell L. (US) | 1991-03-06 | — | — | EP | disclosed |
| WO-1989009833-A1 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | MILLS RANDELL L (US) | 1989-10-19 | — | — | WO | disclosed |
| US-4695588-A | DECARBOXYLASE INHIBITORS | MERCK & CO., INC. (US) | 1987-09-22 | — | — | US | disclosed |
| EP-0040150-B1 | FLUOROMETHYLATED TYROSINE METHYL ESTER | MERRELL TORAUDE ET COMPAGNIE (FR) | 1983-09-21 | — | — | EP | disclosed |
| US-4325961-A | FLUOROMETHYLHISTIDINE, ESTERS, AND SALTS | MERCK & CO., INC. (US) | 1982-04-20 | — | — | US | disclosed |
| US-4288601-A | A-FLUOROMETHYL AMINO ACIDS FROM THE A-HYDROXYMETHYL COMPOUND USING SULFUR TETRAFLUORIDE AND BORON TRIFLUORIDE IN HYDROFLUORIC ACID | MERCK & CO., INC. (US) | 1981-09-08 | — | — | US | disclosed |
| US-4215221-A | A-FLUOROMETHYL AMINO ACIDS FROM THE A-HYDROXYMETHYL COMPOUNDS USING SULFUR TETRAFLUORIDE IN HYDROFLUORIC ACID AND ALUMINUM CHLORIDE | MERCK & CO., INC. (US) | 1980-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | APEH, PAH, ALAD | FOLH1 427/4885NAALAD2 244/4885ACE 569/4885 |
| US-20240033366-A1 | FUNCTIONALIZED SHIGA TOXIN B-SUBUNIT (STxB) PROTEINS AND CONJUGATES THEREOF | STXBP1, STX18, SCTR | FOLH1 1884/4885NAALAD2 1721/4885ACE 2684/4885 |
| US-20130149243-A1 | METHOD FOR PRODUCTION OF F-18 LABELED GLUTAMIC ACID DERIVATIVES | GLUL, SLC18A2, SLC1A2 | FOLH1 12/4885NAALAD2 112/4885ACE 2298/4885 |
| US-20140309424-A1 | DIRECT SYNTHESIS OF 18F-FLUOROMETHOXY COMPOUNDS FOR PET IMAGING AND THE PROVISION OF NEW PRECURSORS FOR DIRECT RADIOSYNTHESIS OF PROTECTED DERIVATIVES OF O-([18F] FLUOROMETHYL) TYROSINE | TH, TYR, FTO | FOLH1 342/4885NAALAD2 592/4885ACE 1637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.